Establishment of efficacy of DOTA-based pretargeted radioimmunotherapy with a bivalent radiohapten for enhanced therapeutic indices

We are currently developing a novel bivalent radiohapten class that we refer to as “gemini” for “twin haptens” to achieve improved therapeutic indices (TIs) via cooperative binding at intratumoral bispecific anti-tumor/anti-DOTA antibody (BsAb).